Want to see SE:ISOFOL full AI Analyst Report?
ISOFOL Stock Chart & Stats
kr0.72
-kr0.10(-6.34%)
At close: 4:00 PM EST
kr0.72
-kr0.10(-6.34%)
Day’s Range― - ―
52-Week Rangekr0.55 - kr1.18
Previous CloseN/A
Volume134.77K
Average Volume (3M)501.89K
Market Cap
kr245.18M
Enterprise Valuekr160.59M
Total Cash (Recent Filing)kr126.99M
Total Debt (Recent Filing)kr0.00
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 25, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding320,491,640
10 Day Avg. Volume847,726
30 Day Avg. Volume501,890
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)1.46
Price to Sales (P/S)0.00
P/FCF Ratio-3.04
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.19
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageA zero-debt balance sheet materially lowers financial distress risk and preserves flexibility to fund clinical programs. Without interest burdens management can allocate cash toward R&D or partnerships, extending runway and enabling strategic options during multi-year drug development cycles.
Reduced Cash Burn TrendOperating cash outflows have fallen meaningfully versus prior years, indicating improved cost discipline and operational efficiencies. A lower annual cash burn lengthens the firm’s runway, reduces near-term financing pressure and increases the probability of reaching clinical inflection points before another capital raise.
Focused Oncology R&DA concentrated strategy on chemotherapy-adjunct oncology candidates aligns resources with a persistent, high-value therapeutic area. This specialization supports clearer development priorities, targeted partner deals, and the potential for asymmetric returns if clinical success yields licensing or commercialization opportunities.
Bears Say
No Recent RevenueA pre-commercial profile with no recurring revenue leaves the company entirely dependent on financing to fund operations. Over the next 2–6 months this structural lack of product revenue means progress hinges on financing and milestone outcomes rather than cash generation from sales.
Persistent Net Losses And Cash BurnLarge and worsening annual losses increase cumulative funding needs and raise dilution risk. Sustained negative operating cash flow pressures management to secure capital before key clinical milestones, making the business sensitive to investor appetite and timing of partner transactions.
Eroding Equity CushionMaterial decline in shareholders' equity reflects accumulated losses and funding dynamics, reducing the balance-sheet buffer against setbacks. A smaller equity base limits capacity to absorb further write‑downs or delays and makes future capital raises more likely and potentially more dilutive.
Isofol Medical AB News
ISOFOL FAQ
What was Isofol Medical AB’s price range in the past 12 months?
Isofol Medical AB lowest stock price was kr0.55 and its highest was kr1.18 in the past 12 months.
What is Isofol Medical AB’s market cap?
Isofol Medical AB’s market cap is kr245.18M.
When is Isofol Medical AB’s upcoming earnings report date?
Isofol Medical AB’s upcoming earnings report date is Aug 25, 2026 which is in 52 days.
How were Isofol Medical AB’s earnings last quarter?
Isofol Medical AB released its earnings results on May 19, 2026. The company reported -kr0.054 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.054.
Is Isofol Medical AB overvalued?
According to Wall Street analysts Isofol Medical AB’s price is currently Overvalued.
Does Isofol Medical AB pay dividends?
Isofol Medical AB does not currently pay dividends.
What is Isofol Medical AB’s EPS estimate?
Isofol Medical AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Isofol Medical AB have?
Isofol Medical AB has 320,491,640 shares outstanding.
What happened to Isofol Medical AB’s price movement after its last earnings report?
Isofol Medical AB reported an EPS of -kr0.054 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.636%.
Which hedge fund is a major shareholder of Isofol Medical AB?
Currently, no hedge funds are holding shares in SE:ISOFOL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Isofol Medical AB
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Technical Analysis
Xintela AB
―
IRLAB Therapeutics AB Class A
―
Modus Therapeutics Holding AB
―
Active Biotech AB
―
Bio-Works Technologies AB
―